Celyad Oncology S.A. (0QFK.L) LSE
0.18
+0.005(+2.94%)
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 33.14M |
| Enterprise Value | 46.48M |
| P/E Ratio | 14.92 |
| PEG Ratio | 0.1 |
| Price/Sales Ratio | 618.14 |
| Price/Book Ratio | 4.93 |
| Enterprise/Revenue | 536.81 |
| Enterprise/EBITDA | -1.61 |
Fiscal Year
| Fiscal Year | December 31, 2024 |
| Most Recent Quarter | June 30, 2025 |
Profitability
| Profit Margin | 38.33 |
| Operating Margin | -339.57 |
Management Effectiveness
| Return On Assets | 0.19 |
| Return On Equity | -2.42 |
Income Statement
| Revenue | 186,000 |
| Revenue/Share | 0 |
| Gross Profit | 919,000 |
| EBITDA | -5.39M |
| Net Income | -5.82M |
| Diluted EPS | -0.14 |
Balance Sheet
| Total Cash | 790,000 |
| Total Cash/Share | 0.04 |
| Total Debt | 831,000 |
| Total Debt/Equity | 0 |
| Current Ratio | 1.92 |
| Book Value Per Share | 0.06 |
Price History
| 52-Week Change | -51.39 |
| 52-Week High | 1.23 |
| 52-Week Low | 0.18 |
| Moving Average 50 Days | 0.51 |
| Moving Average 200 Days | 0.6 |
Statistics
| Average Volume | 1,098 |
| Shares Outstanding | 27.62M |
| % Held by Institutions | N/A |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
